PALATIN TECHNOLOGIES INC
Latest Quote @ Sun May 5 15:59:43 (15 min delayed)
Last Day's Data
Palatin Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of melanocortin (MC)-based therapeutics in the United States. It markets NeutroSpec, a proprietary radiolabeled monoclonal antibody product, for imaging and diagnosing equivocal appendicitis. The company also conducts additional clinical trials with NeutroSpec and evaluating its potential as an imaging agent for osteomyelitis, post-surgical infection, and inflammatory bowel disease. Its PT-141, a clinical development stage nasally-administered peptide, which would be used for the treatment of both male and female sexual dysfunction. In addition, the company has preclinical development programs based on the MC family, which would be used for various therapeutic indications, including obesity and cachexia; and a program for congestive heart failure. The company has a strategic collaboration agreement with Mallinckrodt Imaging for marketing and distributing NeutroSpec; and a collaborative development and marketing agreement with King Pharmaceuticals, Inc., to jointly develop and commercialize PT-141. Palatin Technologies was incorporated in 1986 and is based in Cranbury, New Jersey.